Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
REVA Medical, Inc. (RVA.AX) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/08/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
03/05/2020 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
03/05/2020 8-K Quarterly results
03/03/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/03/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/03/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/03/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/03/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/03/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/03/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/03/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/31/2020 SC 13G/A JPMORGAN CHASE & CO reports a 5.1% stake in REVA MEDICAL, INC.
01/15/2020 8-K Filed for Chapter 11
Docs: "Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered None N/A N/A Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Se...",
"Restructuring Support Agreement, by and between the debtors and the Supporting Lenders",
"REVA Medical Files for Court Approval of Prepackaged Plan of Reorganization"
12/13/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Announcement entitled, “Corporate Update”",
"Announcement entitled, “Corporate Update”"
08/07/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "First Amendment to Credit and Guaranty Agreement",
"Announcement entitled, “REVA Receives Additional Interim Funding”"
04/08/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Amendment #5 to the Exclusive License Agreement Number 2, by and between Rutgers, The State University of New Jersey and the Company",
"Credit and Guaranty Agreement by and between Goldman Sachs International, Various Lenders and the Company",
"dated as of April 2, 2019 by and among EACH OF THE GRANTORS PARTY HERETO and GOLDMAN SACHS INTERNATIONAL, as Collateral Agent",
"Announcement entitled, “REVA Receives Interim Funding and Enters into an Amendment to License Agreement with Rutgers, The State University of New Jersey”"
04/04/2019 SC 13G/A GOLDMAN SACHS GROUP INC reports a 4.9% stake in REVA MEDICAL, INC.
02/25/2019 8-K Quarterly results
02/19/2019 8-K Quarterly results
02/19/2019 8-K Quarterly results
02/14/2019 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2019 5 Senrigan Capital Management Ltd (10% Owner) has filed a Form 5 on REVA Medical, Inc.
02/14/2019 SC 13G Senrigan Capital Group Ltd reports a 26.1% stake in REVA Medical, Inc.
02/04/2019 8-K Quarterly results
01/17/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Executive Employment Agreement, effective as of January 4, 2019, by and between the Company and Leigh Elkolli"
01/04/2019 SC 13G/A JPMORGAN CHASE & CO reports a 7.7% stake in REVA MEDICAL, INC.
01/03/2019 8-K Quarterly results
11/05/2018 10-Q Quarterly Report for the period ended September 30, 2018
11/05/2018 8-K Quarterly results
Docs: "REVA MEDICAL REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS"
09/24/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Presentation entitled “Primary PCI in STEMI with sirolimus eluting FANTOM bioresorbable vascular scaffold first guided with optical coherence tomography – acute results from a FANTOM STEMI pilot study”",
"Presentation entitled “FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – 24-Month Follow-Up Clinical Outcomes Final Results”",
"Presentation entitled “Two-year healing patterns after implantation of the FANTOM bioresorbable scaffold”",
"Presentation entitled “On-going Activities with a Radiopaque Tyrosine-Carbonate-Based Polymeric BRS: Fantom”"
08/30/2018 CT ORDER Form CT ORDER - Confidential treatment order:
08/30/2018 CT ORDER Form CT ORDER - Confidential treatment order:
08/07/2018 10-Q Quarterly Report for the period ended June 30, 2018
08/03/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment #4 to Exclusive License Agreement Number 2, by and between Rutgers, The State University of New Jersey and the Company",
"Amendment #4 to Exclusive License Agreement Number 2, by and between Rutgers, The State University of New Jersey and the Company"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy